Trending topics on coumarin and its derivatives in 2020
Coumarins are naturally occurring molecules with a versatile range of activities. Their
structural and physicochemical characteristics make them a privileged scaffold in medicinal …
structural and physicochemical characteristics make them a privileged scaffold in medicinal …
Mechanisms of resistance to second-generation antiandrogen therapy for prostate cancer: actual knowledge and perspectives
F Pinto, F Dibitetto, M Ragonese, P Bassi - Medical Sciences, 2022 - mdpi.com
Prostate cancer therapy for locally advanced and metastatic diseases includes androgen
deprivation therapy (ADT). Second-generation antiandrogens have a role in castration …
deprivation therapy (ADT). Second-generation antiandrogens have a role in castration …
G-quadruplex DNA contributes to RNA polymerase II-mediated 3D chromatin architecture
High-order chromatin organization plays an important role in biological processes and
disease development. Previous studies revealed a widespread occurrence of guanine …
disease development. Previous studies revealed a widespread occurrence of guanine …
Installation of pargyline, a LSD1 inhibitor, in the HDAC inhibitory template culminated in the identification of a tractable antiprostate cancer agent
R Ojha, IC Chen, CM Hsieh, K Nepali… - Journal of Medicinal …, 2021 - ACS Publications
Pragmatic insertion of pargyline, a LSD1 inhibitor, as a surface recognition part in the HDAC
inhibitory pharmacophore was planned in pursuit of furnishing potent antiprostate cancer …
inhibitory pharmacophore was planned in pursuit of furnishing potent antiprostate cancer …
Development of Biaryl-Containing Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors for Reversing AKR1C3-Mediated Drug Resistance in Cancer Treatment
S He, X Chu, Y Wu, J Jiang, P Fang… - Journal of Medicinal …, 2023 - ACS Publications
Aldo-keto reductase 1C3 (AKR1C3) is correlated with tumor development and
chemotherapy resistance. The catalytic activity of the enzyme has been recognized as one …
chemotherapy resistance. The catalytic activity of the enzyme has been recognized as one …
Aldo-Keto reductase 1C3 inhibitor prodrug improves pharmacokinetic profile and demonstrates in vivo efficacy in a prostate cancer xenograft model
K Maddeboina, SK Jonnalagadda… - Journal of Medicinal …, 2023 - ACS Publications
Aldo-keto reductase 1C3 (AKR1C3) is overexpressed in castration-resistant prostate cancer
where it acts to drive proliferation and aggressiveness by producing androgens. The …
where it acts to drive proliferation and aggressiveness by producing androgens. The …
[HTML][HTML] Inhibition of castration-resistant prostate cancer growth by genistein through suppression of AKR1C3
X Yu, J Yan, Y Li, J Cheng, L Zheng, T Fu… - Food & Nutrition …, 2023 - ncbi.nlm.nih.gov
Background Prostate cancer is the second leading cause of cancer-related death among
males in America. The patients' survival time is significantly reduced after prostate cancer …
males in America. The patients' survival time is significantly reduced after prostate cancer …
Discovery of novel aldo-keto reductase 1C3 inhibitors as chemotherapeutic potentiators for cancer drug resistance
S He, Y Liu, X Chu, Q Li, W Lyu, Y Liu… - ACS medicinal …, 2022 - ACS Publications
As a crucial target which is overexpressed in a variety of cancers, aldo-keto reductase 1C3
(AKR1C3) confers chemotherapeutic resistance to many clinical agents. However, a limited …
(AKR1C3) confers chemotherapeutic resistance to many clinical agents. However, a limited …
Non-coding variants in cancer: mechanistic insights and clinical potential for personalized medicine
M Lange, R Begolli, A Giakountis - Non-coding RNA, 2021 - mdpi.com
The cancer genome is characterized by extensive variability, in the form of Single Nucleotide
Polymorphisms (SNPs) or structural variations such as Copy Number Alterations (CNAs) …
Polymorphisms (SNPs) or structural variations such as Copy Number Alterations (CNAs) …
[HTML][HTML] Structure-guided optimization of 3-hydroxybenzoisoxazole derivatives as inhibitors of Aldo-keto reductase 1C3 (AKR1C3) to target prostate cancer
AC Pippione, S Kovachka, C Vigato, L Bertarini… - European Journal of …, 2024 - Elsevier
AKR1C3 is an enzyme that is overexpressed in several types of radiotherapy-and
chemotherapy-resistant cancers. Despite AKR1C3 is a validated target for drug …
chemotherapy-resistant cancers. Despite AKR1C3 is a validated target for drug …